What does Tempest Therapeutics, Inc. do?

Jun 22 2025 07:15 PM IST
share
Share Via
Tempest Therapeutics, Inc. is a late-stage biopharmaceutical company focused on developing treatments for orphan endocrine diseases. It has a market cap of $28 million and reported a net profit loss of $11 million as of March 2025.
Overview:
Tempest Therapeutics, Inc. is a late-stage biopharmaceutical company focused on developing novel treatments for orphan endocrine diseases within the Pharmaceuticals & Biotechnology industry. Financial Snapshot: Most recent Net Profit: -11 Million (Quarterly Results - Mar 2025) Market cap: USD 28.00 Million (Micro Cap) Key Metrics: P/E: NA (Loss Making) Industry P/E: NA Dividend Yield: 0.00% Debt Equity: -1.46 Return on Equity: -402.40% Price to Book: 2.51 Contact Details: Address: 110 Miller Ave Ste 100, ANN ARBOR MI: 48104-1305 Tel: ['1 734 8459000', '1 734 8648006'] Fax: 1 302 6555049 Website: https://www.millendo.com/
{{stockdata.stock.stock_name.value}} Live

{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)

{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)


Our weekly and monthly stock recommendations are here
Loading...
{{!sm.blur ? sm.comp_name : ''}}
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Entry Price
Target Price
{{sm.target_price }} ({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News
How big is Tempest Therapeutics, Inc.?
Jun 22 2025 06:25 PM IST
share
Share Via